Vizsgálati helyszín
Lille
Lille, 59037, FranciaországMég nincs intézményhez kötve
- 14futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 24 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis10 vizsgálat
- 2. fázis6 vizsgálat
- 1/2. fázis2 vizsgálat
- 4. fázis2 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz9 vizsgálat
- Lezárult8 vizsgálat
- Toboroz5 vizsgálat
- Leállították2 vizsgálat
- Fő szponzor
- Novartis Pharmaceuticals24 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
NCT07203001· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
NCT06514534· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
NCT06444087· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
NCT06157086· Novartis Pharmaceuticals· Forrás
Toboroz
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943· 2/3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
NCT04925479· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
NCT02962414· 3. fázis· Novartis Pharmaceuticals· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in France
NCT07839858· Novartis Pharmaceuticals· Forrás
Lezárult
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
NCT05562934· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941· 4. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
NCT04541589· 2. fázis· Novartis Pharmaceuticals· Forrás
Leállították
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03056755· 2. fázis· Novartis Pharmaceuticals· Forrás
Leállították
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
NCT02967692· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
NCT01828099· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
NCT01742299· 4. fázis· Novartis Pharmaceuticals· Forrás
Hibát jelzek